Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells

Souvick Roy; Shomereeta Roy; Madhabananda Kar; Abhik Chakraborty; AMiT Kumar; Francesco Delogu; Shailendra Asthana; Manoor Prakash Hande; Birendranath Banerjee

doi:10.1016/j.mrgentox.2019.503084

journal article Oct 01, 2019

Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells

Souvick Roy Shomereeta Roy Madhabananda Kar

Abhik Chakraborty AMiT Kumar

Francesco Delogu

Shailendra Asthana Manoor Prakash Hande Birendranath Banerjee

Mutation Research/Genetic Toxicology and Environmental Mutagenesis Vol. 846 pp. 503084 · Elsevier BV

View at Publisher Save 10.1016/j.mrgentox.2019.503084

Topics

No keywords indexed for this article. Browse by subject →

References

53

[1]

Tuljapurkar "The Indian scenario of head and neck oncology - challenging the dogmas" South Asian J. Cancer (2016) 10.4103/2278-330x.187573

[2]

Joshi "Head and neck cancers in developing countries" Rambam Maimonides Med. J. (2014) 10.5041/rmmj.10143

[3]

Roy "Role of beta-catenin in cisplatin resistance, relapse and prognosis of head and neck squamous cell carcinoma" Cell. Oncol. Dordr. (Dordr) (2018)

[4]

Cisplatin in cancer therapy: Molecular mechanisms of action

Shaloam Dasari, Paul Bernard Tchounwou

European Journal of Pharmacology 2014 10.1016/j.ejphar.2014.07.025

[5]

Visacri "Adverse drug reactions and kinetics of cisplatin excretion in urine of patients undergoing cisplatin chemotherapy and radiotherapy for head and neck cancer: a prospective study" Daru (2017) 10.1186/s40199-017-0178-9

[6]

Rosenthal "Altered radiation therapy fractionation, chemoradiation, and patient selection for the treatment of head and neck squamous carcinoma" Semin. Radiat. Oncol. (2004) 10.1053/j.semradonc.2004.01.001

[7]

DeConti "Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)" Cancer Res. (1973)

[8]

Stewart "Human tissue distribution of platinum after cis-diamminedichloroplatinum" Cancer Chemother. Pharmacol. (1982) 10.1007/bf00257239

[9]

Jacobs "Renal handling of cis-diamminedichloroplatinum(II)" Cancer Treat. Rep. (1980)

[10]

Liston "Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies" Clinical Cancer Research (2017) 10.1158/1078-0432.ccr-16-3083

[11]

Hardin "The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors" Lab. Investig. (2017) 10.1038/labinvest.2017.41

[12]

Eun "Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting" BMB Rep. (2017) 10.5483/bmbrep.2017.50.3.222

[13]

Prieto-Vila "Drug resistance driven by cancer stem cells and their niche" Int. J. Mol. Sci. (2017) 10.3390/ijms18122574

[14]

Chang "Cancer stem cells: role in tumor growth, recurrence, metastasis, and treatment resistance" Medicine (2016) 10.1097/md.0000000000004766

[15]

Prud’homme "Cancer stem cells and novel targets for antitumor strategies" Curr. Pharm. Des. (2012) 10.2174/138161212800626120

[16]

Matsui "Cancer stem cell signaling pathways" Medicine (2016) 10.1097/md.0000000000004765

[17]

Takebe "Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update" Nat. Rev. Clin. Oncol. (2015) 10.1038/nrclinonc.2015.61

[18]

Wnt signaling in cancer

T Zhan, N Rindtorff, M Boutros

Oncogene 2017 10.1038/onc.2016.304

[19]

Valkenburg "Wnt/beta-catenin signaling in normal and cancer stem cells" Cancers (2011) 10.3390/cancers3022050

[20]

Lee "Wnt/beta-catenin signalling maintains self-renewal and tumourigenicity of head and neck squamous cell carcinoma stem-like cells by activating Oct4" J. Pathol. (2014) 10.1002/path.4383

[21]

Tian "XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/beta-catenin signaling pathway" Journal of experimental & clinical cancer research: CR (2013) 10.1186/1756-9966-32-100

[22]

Afifi "XAV939: from a small inhibitor to a potent drug bioconjugate when delivered by gold nanoparticles" Bioconjug. Chem. (2014) 10.1021/bc400271x

[23]

Waaler "A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice" Cancer Res. (2012) 10.1158/0008-5472.can-11-3336

[24]

Bao "Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells" PLoS One (2012) 10.1371/journal.pone.0048670

[25]

Busch "Evidence for tankyrases as antineoplastic targets in lung cancer" BMC Cancer (2013) 10.1186/1471-2407-13-211

[26]

Wang "CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/beta-catenin signaling pathway" Cancer Med. (2019)

[27]

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

Ting-Chao Chou

Cancer Research 2010 10.1158/0008-5472.can-09-1947

[28]

Saha "Role of TRF2 in efficient DNA repair, spheroid formation and cancer stem cell maintenance" Oncomedicine (2017) 10.7150/oncm.18373

[29]

Lapytsko "FoCo: a simple and robust quantification algorithm of nuclear foci" BMC Bioinformatics (2015) 10.1186/s12859-015-0816-5

[30]

Newman "Short dysfunctional telomeres impair the repair of arsenite-induced oxidative damage in mouse cells" J. Cell. Physiol. (2008) 10.1002/jcp.21276

[31]

Gyori "OpenComet: an automated tool for comet assay image analysis" Redox Biol. (2014) 10.1016/j.redox.2013.12.020

[32]

O’Callaghan "A quantitative PCR method for measuring absolute telomere length" Biol. Proced. Online (2011) 10.1186/1480-9222-13-3

[33]

Roy "Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells (CSCs) in head and neck squamous cell carcinoma" J. Oral Pathol. Med. (2018) 10.1111/jop.12707

[34]

Comparative Protein Structure Modeling Using MODELLER

Benjamin Webb, Andrej Šali

Current Protocols in Bioinformatics 2016 10.1002/cpbi.3

[35]

ZINC: A Free Tool to Discover Chemistry for Biology

John J. Irwin, Teague Sterling, Michael M. Mysinger et al.

Journal of Chemical Information and Modeling 2012 10.1021/ci3001277

[36]

Frisch (2016)

[37]

Kumar "Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease" Sci. Rep. (2018) 10.1038/s41598-018-22747-2

[38]

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Garrett M. Morris, Ruth Huey, William Lindstrom et al.

Journal of Computational Chemistry 2009 10.1002/jcc.21256

[39]

Asthana "Different molecular mechanisms of inhibition of bovine viral diarrhea virus and hepatitis C virus RNA-dependent RNA polymerases by a novel benzimidazole" Biochemistry (2013) 10.1021/bi400107h

[40]

Yang "Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells" Cancer Res. (2008) 10.1158/0008-5472.can-07-6691

[41]

Yokogi "Wnt/Beta-catenin signal inhibitor HC-1 sensitizes oral squamous cell carcinoma cells to 5-Fluorouracil through reduction of CD44-positive population" Yonago Acta Med. (2016)

[42]

Roy "KLF4 expression in the surgical cut margin is associated with disease relapse of oral squamous cell carcinoma" Oral Surg. Oral Med. Oral Pathol. Oral Radiol. (2019) 10.1016/j.oooo.2019.02.021

[43]

Cepeda "Biochemical mechanisms of cisplatin cytotoxicity" Anticancer Agents Med. Chem. (2007) 10.2174/187152007779314044

[44]

Nagata "Apoptotic DNA fragmentation" Exp. Cell Res. (2000) 10.1006/excr.2000.4834

[45]

Florea "Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects" Cancers (2011) 10.3390/cancers3011351

[46]

Chen "The functional status of DNA repair pathways determines the sensitization effect to cisplatin in non-small cell lung cancer cells" Cell. Oncol. Dordr. (Dordr) (2016)

[47]

Goldstein "MDR1 gene expression in solid tumours" European journal of cancer (Oxford, England: 1990) (1996) 10.1016/0959-8049(96)00100-1

[48]

Bernal "Telomeres: implications for cancer development" Int. J. Mol. Sci. (2018) 10.3390/ijms19010294

[49]

Jia "Mechanisms of drug combinations: interaction and network perspectives" Nat. Rev. Drug Discovery (2009) 10.1038/nrd2683

[50]

Sheng "Advances in computational approaches in identifying synergistic drug combinations" Brief. Bioinformatics (2017)

Showing 50 of 53 references

Cited By

27

Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances

Chen Xue, Qingfei Chu · 2025

Signal Transduction and Targeted Th...

Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance

Milad Ashrafizadeh, Ali Zarrabi · 2020

International Journal of Molecular...

Metrics

27

Citations

53

References

Details

Published: Oct 01, 2019
Vol/Issue: 846
Pages: 503084
License: View

Authors

Department of Applied Mathematics, Delhi Technological University, New Delhi, India

Birendranath Banerjee

Funding

Department of Biotechnology, Government of India Award: BT/P˜17576/MED/30/1690/2016

Virtual National Oral Cancer Institute [Understanding the Disease Biology and Epigenetic Diversity of Oral Cancer in India: (Implications for New Diagnostics and Therapeutics)]

Cite This Article

Souvick Roy, Shomereeta Roy, Madhabananda Kar, et al. (2019). Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 846, 503084. https://doi.org/10.1016/j.mrgentox.2019.503084

Combined treatment with cisplatin and the tankyrase inhibitor XAV-939 increases cytotoxicity, abrogates cancer-stem-like cell phenotype and increases chemosensitivity of head-and-neck squamous-cell carcinoma cells

You May Also Like